Mateusz Kaczmarek, Author at TechStock²

Micron Stock Today (MU): UBS Lifts Price Target to $275 as AI Memory Boom Collides With Capex Fears – November 20, 2025

Micron Technology (NASDAQ: MU) is back in the spotlight on Thursday, November 20, 2025, after UBS sharply raised its price target to $275 on the back of an “unusually tight” memory market and booming AI demand — even as investors

20 November 2025

Artificial Intelligence·Investing·Semiconductors·Stock Market·Technology

Cerence (CRNC) Stock Soars After Q4 2025 Earnings Beat and Bold FY26 AI Guidance – November 20, 2025

Cerence Inc. (NASDAQ: CRNC), the automotive voice and AI specialist, is back in the spotlight today after a powerful earnings-driven rally. Following its fiscal Q4 and full-year 2025 report released after the bell on November 19, Cerence stock is surging

20 November 2025

Artificial Intelligence·Earnings·Financial News·Market Analysis·Stocks

InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025

InMed Pharmaceuticals Inc. (NASDAQ: INM) is back in the spotlight today after a sharp bounce in its share price, driven by fresh preclinical data for its Alzheimer’s disease candidate INM‑901 and heavy speculative trading in the micro‑cap biotech name. On

20 November 2025

Biotechnology·Pharmaceutical News·Stock Market

Nuvation Bio (NUVB) Rockets to 3‑Year High as Wall Street Lifts Price Targets on IBTROZI Momentum – November 20, 2025

Nuvation Bio Inc. has become one of the hottest tickers in biotech this week. On November 20, 2025, NUVB is trading near a three‑year high after a powerful earnings beat, accelerating uptake of its lung‑cancer drug IBTROZI™ (taletrectinib), and a

20 November 2025

Biotech News·Financial Analysis·Investment Strategies·Stock Market·Wall Street

PACS Group (PACS) Stock Soars as Q3 2025 Earnings, Restatement Cleanup and Bullish Guidance Ignite Rally

PACS Group, Inc. (NYSE:PACS) is back in the spotlight on Thursday after delivering strong third‑quarter 2025 results, completing a high‑stakes financial restatement process and unveiling upbeat guidance that has sent the stock to fresh 52‑week highs. PACS Group, Inc. The

20 November 2025

Earnings Reports·Financial Analysis·Investment News·Market Trends·Stock Market

Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) secured a $1.5 billion Ares loan, outlined a three‑year strategy targeting up to 10% revenue growth in 2026, and confirmed a $140 million U.S. manufacturing expansion as it races toward cash breakeven by 2028. Moderna’s pivotal day: liquidity

20 November 2025

Biotechnology·Business News·Healthcare Industry·Investment·Pharmaceuticals

Stock Market Today, Nov. 20, 2025: Nvidia Rally vs Fed Caution on FOMC Minutes, Trade Gap and Oil

WeShop (WSHP) Stock Today, 20 November 2025: U.S. App Launch, 500% Rally and Sharp Pre‑Market Selloff

WeShop Holdings Limited (NASDAQ: WSHP) is back in the spotlight today, 20 November 2025, as its first U.S. social‑commerce app goes live, the company prepares to ring the Nasdaq Closing Bell in Times Square, and its newly listed shares swing

20 November 2025

Financial News·Investing·Market Trends·Stock Market·Technology

Stock Market Today, Nov. 20, 2025: Nvidia Rally vs Fed Caution on FOMC Minutes, Trade Gap and Oil

Nvidia’s blockbuster earnings have lit a fire under U.S. stock futures this Thursday, but a hawkish set of Federal Reserve minutes, a sharply narrower U.S. trade deficit and fresh crude oil inventory data are all reminding investors that the macro

20 November 2025

Economic News·Federal Reserve·NVIDIA·Oil Prices·Stock Market

Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed”) is back in the spotlight today after announcing a “major breakthrough” in its ibogaine supply chain and emerging as one of the more active healthcare micro‑caps in pre‑market trading. The Nasdaq‑listed psychedelic biotech

20 November 2025

Biotechnology·Clinical Trials·Pharmaceuticals·Stock Market

Bath & Body Works (BBWI) Stock Hit by Q3 2025 Miss, Holiday Sales Warning and New ‘Consumer First’ Turnaround Plan

Bath & Body Works, Inc. (NYSE: BBWI) shares swung wildly on Thursday after the specialty retailer reported softer-than-expected third-quarter 2025 results, slashed its full‑year outlook and warned of weaker holiday demand, even as it unveiled an ambitious new transformation strategy

20 November 2025

Earnings Reports·Investment News·Retail Industry·Stock Market

Block, Inc. (XYZ) Stock Jumps on $5 Billion Buyback and Bold 2028 Profit Targets – 20 November 2025

Block, Inc. (NYSE: XYZ) — the Jack Dorsey‑led fintech behind Cash App and Square — is back in the spotlight today after unveiling an ambitious three‑year growth roadmap and a fresh $5 billion share repurchase authorization. The new plan, presented

20 November 2025

Company Earnings·Financial Analysis·Investment Strategies·Market Trends·Stock Market News

ZIM Integrated Shipping Services (ZIM) Q3 2025 Earnings: Profit Slumps, Guidance Raised and Dividend Declared

ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) has reported sharply lower third‑quarter profit as container freight rates continue to normalize, but the carrier surprised markets by raising its full‑year 2025 outlook and declaring another cash dividend. PR Newswire The mixed

20 November 2025

Dividends·Earnings Reports·Financial Analysis·Stock Market